MWM
FLGT icon

Mascoma Wealth Management’s Fulgent Genetics FLGT Stock Holding History

Mascoma Wealth Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,504
Closed -$44.5K – 526
2023
Q1 		$44.5K Hold
1,504
– – 0.01% 248
2022
Q4 		$44.8K Hold
1,504
– – 0.01% 244
2022
Q3 		$57K Hold
1,504
– – 0.02% 213
2022
Q2 		$82K Hold
1,504
– – 0.03% 192
2022
Q1 		$94K Buy
+1,504
New +$99K 0.03% 193

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Mascoma Wealth Management's FLGT Position: Q2 2023 in Review

Mascoma Wealth Management sold out of Fulgent Genetics (FLGT) in Q2 2023, closing a stake of 1,504 shares — an estimated $44.5K sold.

Mascoma Wealth Management first reported a position in FLGT in Q1 2022 and held it in 5 quarters. The position peaked at $94K in Q1 2022. 214 funds tracked by Wall St. Rank hold FLGT as of Q2 2023.

  • Mascoma Wealth Management reported no remaining Fulgent Genetics position as of Q2 2023 after selling out during the quarter.
  • Mascoma Wealth Management sold 1,504 Fulgent Genetics shares in Q2 2023, an estimated $44.5K.
  • Mascoma Wealth Management first reported a position in Fulgent Genetics in Q1 2022 and held it in 5 quarters.
  • Mascoma Wealth Management's Fulgent Genetics position peaked at $94K in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2023.

Based on Mascoma Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.